12/4
01:48 am
agen
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript [Seeking Alpha]
11/26
02:01 pm
agen
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
04:34 pm
agen
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL [Yahoo! Finance]
Low
Report
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL [Yahoo! Finance]
11/19
04:01 pm
agen
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Low
Report
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
11/18
08:53 am
agen
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC [Yahoo! Finance]
Low
Report
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC [Yahoo! Finance]
11/18
08:41 am
agen
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
Low
Report
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
11/14
01:10 pm
agen
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
07:41 am
agen
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances [Yahoo! Finance]
Medium
Report
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances [Yahoo! Finance]
11/10
07:30 am
agen
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Medium
Report
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
11/5
01:47 pm
agen
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Low
Report
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
10/20
08:21 am
agen
Agenus (NASDAQ:AGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Agenus (NASDAQ:AGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/17
08:00 am
agen
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
Medium
Report
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
10/16
07:48 am
agen
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
Low
Report
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
10/3
03:19 pm
agen
Agenus (NASDAQ:AGEN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agenus (NASDAQ:AGEN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/10
08:00 am
agen
Agenus (NASDAQ:AGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Medium
Report
Agenus (NASDAQ:AGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
9/9
07:54 am
agen
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer [Yahoo! Finance]
High
Report
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer [Yahoo! Finance]
9/9
07:43 am
agen
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
High
Report
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
9/9
07:13 am
agen
GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada [Yahoo! Finance]
High
Report
GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada [Yahoo! Finance]